1
|
Ortuzar A, Fox ML, Vera JA, Lorenzo Vizcaya Á, Marín Sánchez A, Llopis Calatayud I, Carbonell S, Álvarez-Larrán A, Mata Serna R, Marco Buades JE, Quiroz Cervantes K, Martínez Hellín Á, Blum Domínguez A, Caballero Navarro G, Cáceres Sansaloni A, Guerrero Fernández L, Muñoz Linares C, Gasior Kabat M, Pérez López R, Fernández Rodríguez Á, Martínez Bilbao C, Cobo Rodríguez MT, Díaz Á, Durán MA, Santaliestra Tomas M, García-Gutierrez V, Magro Mazo E, Hernández-Boluda JC, Segura A, Raya JM, Navas Elorza B, Osorio S. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain. Ann Hematol 2023; 102:447-456. [PMID: 36422672 PMCID: PMC9686214 DOI: 10.1007/s00277-022-05044-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Accepted: 11/08/2022] [Indexed: 11/25/2022]
Abstract
The SARS-CoV-2 pandemic has favored the expansion of telemedicine. Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN) might be good candidates for virtual follow-up. In this study, we aimed to analyze the follow-up of patients with Ph-MPN in Spain during COVID-19, its effectiveness, and acceptance among patients. We present a multicenter retrospective study from 30 centers. Five hundred forty-one patients were included with a median age of 67 years (yr). With a median follow-up of 19 months, 4410 appointments were recorded. The median of visits per patient was 7 and median periodicity was 2.7 months; significantly more visits and a higher frequency of them were registered in myelofibrosis (MF) patients. 60.1% of visits were in-person, 39.5% were by telephone, and 0.3% were videocall visits, with a predominance of telephone visits for essential thrombocythemia (ET) and polycythemia vera (PV) patients over MF, as well as for younger patients (< 50 yr). The proportion of phone visits significantly decreased after the first semester of the pandemic. Pharmacological modifications were performed only in 25.7% of the visits, and, considering overall management, ET patients needed fewer global treatment changes. Telephone contact effectiveness reached 90% and only 5.4% required a complementary in-person appointment. Although 56.2% of the cohort preferred in-person visits, 90.5% of our patients claimed to be satisfied with follow-up during the pandemic, with an 83% of positive comments. In view of our results, telemedicine has proven effective and efficient, and might continue to play a complementary role in Ph-MPN patients' follow-up.
Collapse
Affiliation(s)
- Ariana Ortuzar
- Hematology Department, Gregorio Marañón General University Hospital, Madrid, Spain
| | - María Laura Fox
- Hematology Department, Vall d’Hebron University Hospital, Barcelona, Spain
| | - Juan Antonio Vera
- Hematology Department, Virgen Macarena University Hospital, Seville, Spain
| | | | | | | | - Sara Carbonell
- Hematology Department, Hospital Clinic of Barcelona, Barcelona, Spain
| | | | - Raquel Mata Serna
- Hematology Department, Fundación Jiménez-Díaz University Hospital, Madrid, Spain
| | | | | | | | - Alejandra Blum Domínguez
- Hematology Department, Grupo Recoletas Hospital (Campo Grande, Zamora, Palencia Y Segovia), Palencia, Spain
| | | | | | | | | | | | - Raúl Pérez López
- Hematology Department, Clínico Virgen de La Arrixaca University Hospital, Murcia, Spain
| | | | | | | | - Álvaro Díaz
- Hematology Department, La Fe University and Polytechnic Hospital, Valencia, Spain
| | - M. Antonia Durán
- Hematology Department, Son Espases University Hospital, Palma de Mallorca, Spain
| | | | | | - Elena Magro Mazo
- Hematology Department, Príncipe de, Asturias University Hospital, Alcalá de Henares, Spain
| | | | - Adrián Segura
- Hematology Department, Doctor Negrín University Hospital, Gran Canaria, Spain
| | - José María Raya
- Hematology Department, Canarias University Hospital, Tenerife, Spain
| | | | - Santiago Osorio
- Hematology Department, Gregorio Marañón General University Hospital, Madrid, Spain
| |
Collapse
|
2
|
Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade‐Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas M, Bonifacio M, Alvarez‐Larran A, Kiladjian J, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia‐Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez‐Boluda JC, Osorio S, Carreno‐Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nałęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto‐Garcia N, Rambaldi A, Vannucchi AM. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. Am J Hematol 2022; 97:E470-E473. [PMID: 36111658 PMCID: PMC9538387 DOI: 10.1002/ajh.26732] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 09/08/2022] [Accepted: 09/13/2022] [Indexed: 01/31/2023]
Affiliation(s)
- Tiziano Barbui
- FROM Research FoundationPapa Giovanni XXIII HospitalBergamoItaly
| | | | - Arianna Ghirardi
- FROM Research FoundationPapa Giovanni XXIII HospitalBergamoItaly
| | - Alessandra Iurlo
- Hematology DivisionFoundation IRCCS Ca' Granda Ospedale Maggiore PoliclinicoMilanItaly
| | - Marta Anna Sobas
- Department of Hematology, Blood Neoplasms and Bone Marrow TransplantationWroclaw Medical UniversityWrocławPoland
| | - Elena Maria Elli
- Hematology Division and Bone Marrow Transplant Unit, San Gerardo HospitalASST MonzaMonzaItaly
| | - Elisa Rumi
- Department of molecular medicineUniversity of PaviaPaviaItaly
| | - Valerio De Stefano
- Diagnostic Imaging, Oncological Radiotherapy, and Hematology DepartmentFondazione Universitaria Policlinico A. Gemelli ‐ IRCCS ‐ Catholic University of Sacred Heart of RomeRomeItaly
| | - Francesca Lunghi
- Hematology and BMT UnitUniversity Vita‐Salute San Raffaele, San Raffaele Scientific InstituteMilanItaly
| | - Monia Marchetti
- Division of HematologyAOU SS. Antonio e Biagio e C. ArrigoAlessandriaItaly
| | - Rosa Daffini
- Division of HematologyASST‐Spedali CiviliBresciaItaly
| | | | - Beatriz Cuevas
- Division of HematologyHospital Universitario de BurgosBurgosSpain
| | - Maria Laura Fox
- Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO)Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital CampusBarcelonaSpain
| | | | - Francesca Palandri
- Institute of HematologyIRCCS Azienda Ospedaliero‐Universitaria di BolognaBolognaItaly
| | - Paola Guglielmelli
- Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria CareggiUniversity of FlorenceFlorenceItaly
| | - Giulia Benevolo
- Hematology UnitAOU Città della Salute e della ScienzaTurinItaly
| | - Claire Harrison
- Department of HaematologyGuy's and St. Thomas' NHS Foundation TrustLondonUK
| | | | | | | | | | | | - Andrea Patriarca
- Division of Hematology, Department of Translational MedicineAOU Maggiore della CaritàNovaraItaly
| | | | - Martin Griesshammer
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative CareJohannes Wesling Medical CenterMindenGermany
| | | | | | - Elena Magro Mazo
- Division of HematologyHospital Universitario Principe de AsturiasAlcalà de Henares (Madrid)Spain
| | | | | | | | | | - Miguel Sagues Serrano
- Division of HematologyICO L'Hospitalet‐Hospital Moises BroggiSant Joan Despì (Barcelona)Spain
| | - Rajko Kusec
- Department of haematology, Clinic of internal medicineUniversity Hospital Dubrava‐School of Medicine University of ZagrebZagrebCroatia
| | | | - Anna Angona
- Division of HematologyICO Girona Hospital Josep TruetaGironaSpain
| | - Blanca Xicoy Cirici
- Division of HematologyICO Hospital Germans Trias i PujolBadalona (Barcelona)Spain
| | - Emma Lopez Abadia
- Division of HematologyHospital General de ElcheElche (Alicante)Spain
| | - Steffen Koschmieder
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of MedicineRWTH Aachen UniversityAachenGermany
| | - Daniele Cattaneo
- Hematology DivisionFoundation IRCCS Ca' Granda Ospedale Maggiore PoliclinicoMilanItaly,Department of Oncology and HematologyUniversità degli Studi di MilanoMilanItaly
| | - Cristina Bucelli
- Hematology DivisionFoundation IRCCS Ca' Granda Ospedale Maggiore PoliclinicoMilanItaly
| | - Edyta Cichocka
- Department of Hematology and Bone Marrow TransplantationNicolaus Copernicus HospitalTorunPoland
| | | | - Fabrizio Cavalca
- Hematology Division and Bone Marrow Transplant Unit, San Gerardo HospitalASST MonzaMonzaItaly
| | - Oscar Borsani
- Department of molecular medicineUniversity of PaviaPaviaItaly
| | - Silvia Betti
- Diagnostic Imaging, Oncological Radiotherapy, and Hematology DepartmentFondazione Universitaria Policlinico A. Gemelli ‐ IRCCS ‐ Catholic University of Sacred Heart of RomeRomeItaly
| | - Marta Bellini
- Hematology and Bone Marrow Transplant UnitASST Papa Giovanni XXIIIBergamoItaly
| | | | - Alessandro Rambaldi
- Department of Oncology and HematologyUniversità degli Studi di MilanoMilanItaly,Hematology and Bone Marrow Transplant UnitASST Papa Giovanni XXIIIBergamoItaly
| | - Alessandro Maria Vannucchi
- Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria CareggiUniversity of FlorenceFlorenceItaly
| |
Collapse
|
3
|
Gasior Kabat M, Bueno D, Sisinni L, De Paz R, Mozo Y, Perona R, Arias-Salgado EG, Rosich B, Marcos A, Romero AB, Constanzo A, Jiménez-Yuste V, Pérez-Martínez A. Selective T-cell depletion targeting CD45RA as a novel approach for HLA-mismatched hematopoietic stem cell transplantation in pediatric nonmalignant hematological diseases. Int J Hematol 2021; 114:116-123. [PMID: 33772729 DOI: 10.1007/s12185-021-03138-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 03/13/2021] [Accepted: 03/17/2021] [Indexed: 11/28/2022]
Abstract
Severe aplastic anemia and congenital amegakaryocytic thrombocytopenia are rare bone marrow failure syndromes. Treatment for aplastic anemia consists of hematopoietic stem cell transplantation (HSCT) from a matched sibling donor or immunosuppressant drugs if there is no donor available. Congenital amegakaryocytic thrombocytopenia is a rare autosomal recessive disease that causes bone marrow failure and has limited treatment options, except for transfusion support and HSCT. In the absence of a suitable matched sibling donor, matched-unrelated, haploidentical, or mismatched donors may be considered. A 2-step partial T-cell-depletion strategy can remove CD45RA+ naïve T cells responsible for graft-versus-host disease (GvHD) while preserving memory T cells. Five patients underwent transplantation using this strategy with rapid neutrophil and platelet recovery. Acute and chronic GvHD ≥ grade 2 appeared in two and one patient, respectively. No severe infections were observed before day + 100. A high (60%) incidence of transplant-associated microangiopathy was observed. Three patients (60%) remain alive, with a median follow-up of 881 (range 323-1248) days. CD45RA-depleted HSCT is a novel approach for patients lacking a suitable matched donor; however, further improvements are needed.
Collapse
Affiliation(s)
- Mercedes Gasior Kabat
- Hematology Department, La Paz University Hospital, Paseo De La Castellana 261, 28046, Madrid, Spain.
| | - David Bueno
- Pediatric Onco-Hematology Department, La Paz University Hospital, Madrid, Spain
| | - Luisa Sisinni
- Pediatric Onco-Hematology Department, La Paz University Hospital, Madrid, Spain
| | - Raquel De Paz
- Hematology Department, La Paz University Hospital, Paseo De La Castellana 261, 28046, Madrid, Spain
| | - Yasmina Mozo
- Pediatric Onco-Hematology Department, La Paz University Hospital, Madrid, Spain
| | - Rosario Perona
- Foundation for Biomedical Research CSIC/UAM, IDIPaz, CIBER on Rare Diseases, La Paz University Hospital, Madrid, Spain
| | - Elena G Arias-Salgado
- Foundation for Biomedical Research CSIC/UAM, IDIPaz, CIBER on Rare Diseases, La Paz University Hospital, Madrid, Spain
| | - Blanca Rosich
- Pediatric Onco-Hematology Department, La Paz University Hospital, Madrid, Spain
| | - Antonio Marcos
- Hematology Department, La Paz University Hospital, Paseo De La Castellana 261, 28046, Madrid, Spain
| | - Ana Belén Romero
- Hematology Department, La Paz University Hospital, Paseo De La Castellana 261, 28046, Madrid, Spain
| | - Aida Constanzo
- Hematology Department, La Paz University Hospital, Paseo De La Castellana 261, 28046, Madrid, Spain
| | - Víctor Jiménez-Yuste
- Hematology Department, La Paz University Hospital, Paseo De La Castellana 261, 28046, Madrid, Spain
| | | |
Collapse
|
4
|
Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J 2021; 11:21. [PMID: 33563901 PMCID: PMC7871138 DOI: 10.1038/s41408-021-00417-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 12/15/2020] [Accepted: 01/19/2021] [Indexed: 12/12/2022] Open
Abstract
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.
Collapse
Affiliation(s)
- Tiziano Barbui
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
| | - Valerio De Stefano
- Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico "A. Gemelli" IRCCS, Rome, Italy
| | | | - Alessandra Iurlo
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Arianna Masciulli
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | | | - Arianna Ghirardi
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - Alberto Ferrari
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | | | - Elena Maria Elli
- Hematology Division and Bone Marrow Transplant, San Gerardo Hospital, ASST Monza, Monza, Italy
| | | | | | | | - Francesca Palandri
- Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italia
| | - Giulia Benevolo
- AOU Città della Salute e della Scienza di Torino, Torino, Italy
| | | | - Maria Laura Fox
- Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain
| | | | | | - Elisa Rumi
- Department of molecular medicine, University of Pavia, Pavia, Italy
| | | | | | | | | | | | | | - Marta Anna Sobas
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wrocław, Poland
| | | | | | | | - Anna Angona
- ICO Girona Hospital Josep Trueta, Girona, Spain
| | - Elena Magro Mazo
- Hospital Universitario Principe de Asturias, Alcalà de Henares, Madrid, Spain
| | - Steffen Koschmieder
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| | | | | | | | | | - Blanca Xicoy Cirici
- Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Joseo Carreras Leukemia Research Institute, Badalona (Barcelona) Spain, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Paola Guglielmelli
- Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
| | | | - Daniele Cattaneo
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | - Fabrizio Cavalca
- Hematology Division and Bone Marrow Transplant, San Gerardo Hospital, ASST Monza, Monza, Italy
| | | | | | | | | | - Silvia Betti
- Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico "A. Gemelli" IRCCS, Rome, Italy
| | | | - Alessandro Rambaldi
- ASST Papa Giovanni XXIII, Bergamo, Italy
- Università degli Studi di Milano, Milano, Italy
| | - Alessandro Maria Vannucchi
- Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
| |
Collapse
|
5
|
Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia 2021; 35:485-493. [PMID: 33414483 PMCID: PMC7789078 DOI: 10.1038/s41375-020-01107-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 10/29/2020] [Accepted: 11/27/2020] [Indexed: 11/13/2022]
Abstract
We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19.
Collapse
Affiliation(s)
- Tiziano Barbui
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
| | - Alessandro Maria Vannucchi
- Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
| | | | - Alessandra Iurlo
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Arianna Masciulli
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | | | - Arianna Ghirardi
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - Alberto Ferrari
- FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | | | - Elena Elli
- Ospedale San Gerardo, ASST Monza, Monza, Italy
| | | | | | | | - Francesca Palandri
- Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italia
| | - Giulia Benevolo
- AOU Città della Salute e della Scienza di Torino, Torino, Italy
| | | | - Maria Laura Fox
- Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain
| | | | | | - Elisa Rumi
- Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | | | | | | | | | | | | | - Marta Anna Sobas
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | | | | | | | - Anna Angona
- ICO Girona Hospital Josep Trueta, Girona, Spain
| | - Elena Magro Mazo
- Hospital Universitario Principe de Asturias, Alcalà de Henares, Madrid, Spain
| | - Steffen Koschmieder
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| | | | | | | | | | | | - Paola Guglielmelli
- Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
| | | | - Daniele Cattaneo
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | | | | | | | | | | | - Silvia Betti
- Fondazione Policlinico "A. Gemelli" IRCCS, Rome, Italy
| | | | | | - Alessandro Rambaldi
- ASST Papa Giovanni XXIII, Bergamo, Italy.,Università degli Studi di Milano, Milano, Italy
| |
Collapse
|
6
|
Pérez Encinas MM, Sobas M, Gómez-Casares MT, Abuin Blanco A, Noya Pereira MS, Raya JM, Andrade-Campos MM, Álvarez Larrán A, Lewandowski K, Łukasz S, Hernández Boluda JC, Ferrer-Marín F, Fox ML, Gołos A, Gasior Kabat M, Magro Mazo E, Czyż A, Martín Martín A, Bellosillo Paricio B, Quinteiro García C, González Martín JM, Stuckey R. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study. Eur J Haematol 2020; 106:371-379. [PMID: 33275803 DOI: 10.1111/ejh.13561] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 11/30/2020] [Accepted: 12/01/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVES In patients with essential thrombocythemia (ET), after the JAK2V617F driver mutation, mutations in CALR are common (classified as type 1, 52-bp deletion or type 2, 5-bp insertion). CALR mutations have generally been associated with a lower risk of thrombosis. This study aimed to confirm the impact of CALR mutation type on thrombotic risk. METHODS We retrospectively investigated 983 ET patients diagnosed in Spanish and Polish hospitals. RESULTS With 7.5 years of median follow-up from diagnosis, 155 patients (15.8%) had one or more thrombotic event. The 5-year thrombosis-free survival (TFS) rate was 83.8%, 91.6% and 93.9% for the JAK2V617F, CALR-type 1 and CALR-type 2 groups, respectively (P = .002). Comparing CALR-type 1 and CALR-type 2 groups, TFS for venous thrombosis was lower in CALR-type 1 (P = .046), with no difference in TFS for arterial thrombosis observed. The cumulative incidence of thrombosis was significantly different comparing JAK2V617F vs CALR-type 2 groups but not JAK2V617F vs CALR-type 1 groups. Moreover, CALR-type 2 mutation was a statistically significant protective factor for thrombosis with respect to JAK2V617F in multivariate logistic regression (OR: 0.45, P = .04) adjusted by age. CONCLUSIONS Our results suggest that CALR mutation type has prognostic value for the stratification of thrombotic risk in ET patients.
Collapse
Affiliation(s)
- Manuel M Pérez Encinas
- Hematology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Marta Sobas
- Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | - María Teresa Gómez-Casares
- Hematology Department, Hospital Universitario de Gran Canaria Dr.Negrín, Las Palmas de Gran Canaria, Spain
| | - Aitor Abuin Blanco
- Hematology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | | | - José María Raya
- Hematology Department, Hospital, Universitario de Canarias, Santa Cruz de Tenerife, Spain
| | | | | | - Krzysztof Lewandowski
- Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences, Poznan, Poland
| | - Szukalski Łukasz
- Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland
| | | | | | - María Laura Fox
- Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain
| | - Aleksandra Gołos
- Department of Clinical Oncology and Chemotherapy, Magodent Hospital, Warsaw, Poland
| | | | - Elena Magro Mazo
- Hematology Department, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | - Anna Czyż
- Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | | | | | - Celsa Quinteiro García
- Genomics Laboratory, Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain
| | | | - Ruth Stuckey
- Hematology Department, Hospital Universitario de Gran Canaria Dr.Negrín, Las Palmas de Gran Canaria, Spain
| |
Collapse
|
7
|
Lázaro Del Campo P, Ramírez López A, de la Cruz Benito B, de Paz Arias R, de Soto Álvarez T, Sánchez Vadillo I, Humala Barbier K, García Pérez E, Dos Santos Ortas A, López de la Guía A, Gasior Kabat M, Baltasar Tello P, Jiménez Yuste V, Canales Albendea M. Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid. Expert Rev Hematol 2020; 14:1-5. [PMID: 33280467 DOI: 10.1080/17474086.2021.1858789] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
8
|
Gasior Kabat M, Ahmad SH, Assir MZ, Ahmad HI, Akram J, Wechalekar A, Hughes D, McNamara C. Clinicopathologic characteristics and outcomes of patients experiencing severe pyrimethamine poisoning. Leuk Lymphoma 2014; 55:2410-2. [PMID: 24491025 DOI: 10.3109/10428194.2014.887712] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|